pharma · Facioscapulohumeral Muscular Dystrophy (FSHD) · Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) · FULC
Fulcrum Therapeutics
Fulcrum Therapeutics trial registry — 14 ClinicalTrials.gov studies with program phase, status, and indication context.
26 Landsdowne St, Cambridge, Massachusetts 02139, US HQ
2016 Founded
73 Employees
Public company Type
FULC · NYSE Ticker
Company details
- Status
- Public
- HQ
- 26 Landsdowne St, Cambridge, Massachusetts 02139, US
- Founded
- 2016
- Employees
- 73
- Programs
- 12
- Drugs
- 8
- Patents
- 11
Fulcrum Therapeutics clinical trials
Registry index of 14 ClinicalTrials.gov studies linked to Fulcrum Therapeutics programs — each row shows trial ID, program name, phase, status, and indication.
Fulcrum Therapeutics trial registry — 14 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Fulcrum Therapeutics.
-
1821-FSH-301 — Phase 3
Clinical update -
Pociredir oral capsule(s) — Phase 1
Clinical update -
Losmapimod oral tablet — Phase 2
Clinical update -
Losmapimod oral tablet — Phase 3
Clinical update -
FTX-6058/placebo oral capsule(s) — Phase 1
Clinical update -
Losmapimod — Phase 2
Clinical update -
Losmapimod — Phase 2
Clinical update -
Losmapimod — Phase 3
Clinical update